Journal of Adolescent Health
Volume 43, Issue 5 , Pages 421-424 , November 2008

A Review of Adapalene in the Treatment of Acne Vulgaris

  • Cynthia E. Irby, B.A.

      Affiliations

    • Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine; Winston-Salem, North Carolina
    • ,
  • Brad A. Yentzer, M.D.

      Affiliations

    • Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine; Winston-Salem, North Carolina
    • ,
  • Steven R. Feldman, M.D., Ph.D.

      Affiliations

    • Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine; Winston-Salem, North Carolina
    • Department of Public Health Sciences, Center for Dermatology Research, Wake Forest University School of Medicine; Winston-Salem, North Carolina
    • Department of Pathology, Center for Dermatology Research, Wake Forest University School of Medicine; Winston-Salem, North Carolina
    • Corresponding Author InformationAddress correspondence to: Steven R. Feldman, M.D., Ph.D., Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071

Received 7 January 2008 ,Accepted 9 June 2008.

References 

  1. Webster GF. The pathophysiology of acne. Cutis. 2005;76(2 Suppl):4–7
  2. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):43–49
  3. Czernielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):5–12
  4. Galderma Laboratories L.P. Differin (adapalene gel) Gel, 0.3% Product Insert. http://www.differin.com/AboutDifferin/ProductInsert_Gel03.aspxAccessed October 14, 2007
  5. Akhavan A, Bershad S. Topical acne drugs: Review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4:473–492
  6. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(Suppl 52):8–11
  7. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139(Suppl 52):34–40
  8. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997;36(6 Pt 2):S96–S103
  9. Bouclier M, Chatelus A, Ferracin J, et al. Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standardized image analysis technique. Skin Pharmacol. 1991;4:65–73
  10. Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol. 1998;139(Suppl 52):41–47
  11. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998;139(Suppl 52):26–33
  12. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatol Treat. 2001;12:149–157
  13. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006;54:242–250
  14. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: A randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006;142:597–602
  15. Wolf JE, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: A multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003;49(3 Suppl):S211–S217
  16. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: A multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4:138–146
  17. Wolf JE. Safety and tolerability in the MORE trial. Cutis. 2006;78(1 Suppl):19–25
  18. Balkrishnan R, Fleischer AB, Paruthi S, Feldman SR. Physicians underutilize topical retinoids in the management of acne vulgaris: Analysis of U.S. National Practice Data. J Dermatol Treat. 2003;14:172–176
  19. Yentzer BA, Irby CE, Fleischer AB, Feldman SR. Differences in acne treatment prescribing patterns of pediatricians and dermatologists: An analysis of nationally representative data. Pediatr Dermatol. 2008;In press
  20. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl Part 2):S1–S37
  21. Drugstore.com http://www.drugstore.comAccessed May 8, 2008

 Potential conflicts of interest: Dr. Feldman has received research, speaking and/or consulting support from several manufacturers of topical retinoids including Galderma, OrthoNeutrogena, and Stiefel. The Center for Dermatology Research is supported by an educational grant from Galderma Laboratories, L.P. Dr. Yentzer and Ms. Irby have no conflicts to disclose.

PII: S1054-139X(08)00271-1

doi: 10.1016/j.jadohealth.2008.06.005

Journal of Adolescent Health
Volume 43, Issue 5 , Pages 421-424 , November 2008

Article Tools